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Abstract
Background—Elevated hepatic oxidative stress and lipid peroxidation levels caused by 
increased hepatic Cytochrome P-450 2E1 (CYP2E1) enzyme activity has been speculated to play a 
role in the pathogenesis of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic 
steatohepatitis (NASH). But studies of lipid peroxidation and CYP2E1 in children are lacking.
Aim—To compare hepatic lipid peroxidation and hepatic CYP2E1 protein content in liver 
biopsies from children with NAFLD and two control groups.
Study—Liver biopsies from 59 children with NAFLD (49 with NASH), 10 children with normal 
liver histology, and 9 children with chronic hepatitis C infection (HCV) were examined. Hepatic 
malondialdehyde (MDA, a measure of lipid peroxidation) levels and CYP2E1 protein content 
were quantitated, as a percent of total area, by immunohistochemical staining of liver biopsy 
material followed by digital image quantitation.
Results—Lipid peroxidation was significantly greater in NAFLD liver biopsies (46.7 ± 20.8%) 
compared to liver biopsies from children with normal liver histology (7.6 ± 9.4%; p<0.001) or 
HCV (7.7 ± 7.6%; p<0.001). However, hepatic CYP2E1 was not higher in NAFLD biopsies 
compared to other groups (p=). Among children with NAFLD, lipid peroxidation and CYP2E1 
protein content were not different between biopsies with and without NASH. The BMI was 
independently associated with hepatic lipid peroxidation (r=0.549; p<0.001).
Conclusions—Hepatic lipid peroxidation is increased in children with NAFLD but this is not 
related to hepatic CYP2E1. Lack of difference in lipid peroxidation among different NAFLD 
subgroups argues against its role in the disease progression.
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Introduction
The epidemic incidence of overweight and obesity in the pediatric population has likely 
contributed to the rise of nonalcoholic fatty liver disease (NAFLD) as the most prevalent 
chronic liver condition in children today1–2. In fact, estimates for the current prevalence of 
NAFLD in children and adolescents range from 2.6% to 9.6%, depending on the 
characteristics of the patient population and the diagnostic tests used3. NAFLD, including 
both nonalcoholic steatohepatitis (NASH) and simple steatosis (non-NASH NAFLD), are of 
great importance in the pediatric population due to the potential for progression to cirrhosis 
in young and middle-aged adults4–5.
NAFLD represents an entire spectrum of histological features upon liver biopsy, ranging 
from simple fatty liver to serious pathological findings including advanced fibrosis and 
cirrhosis6. The histological findings in adult NAFLD have been well characterized, but 
diagnostic criteria in children are less clear. Schwimmer et al. first proposed two different 
types of nonalcoholic steatohepatitis in children: type 1 (“adult”) NASH associated with 
steatosis, ballooning degeneration, and perisinusoidal fibrosis in the absence of portal 
features, and type 2 (“pediatric”) NASH characterized by steatosis, portal inflammation, and 
portal fibrosis in the absence of ballooning degeneration and perisinusoidal fibrosis7. Type 1 
NASH was found to be more common in older children, girls, and Caucasians, while type 2 
NASH was observed more often in younger and heavier children, boys, and non-Whites7. 
Findings from subsequent studies have confirmed this unique portal-based pattern of disease 
in children and suggested that the presence of overlapping features of both type 1 and type 2 
NASH may be more commonly observed than one type alone8–12.
Regardless of disease type, understanding of the pathogenesis, progression, and response to 
treatment of pediatric NAFLD remains a significant unmet medical need. One pathway 
commonly implicated in the development of adult NAFLD is oxidative stress and 
inflammation, leading to increased lipid peroxidation. Indeed, both hepatic and systemic 
lipid peroxidation levels are elevated in adults with non-NASH NAFLD and NASH13–16. A 
key hepatic enzyme capable of producing oxidative stress and lipid peroxidation is 
cytochrome P-450 2E1 (CYP2E1), a microsomal enzyme that functions in fatty acid 
hydroxylation and drug metabolism. Both expression and activity of CYP2E1 is increased in 
animal models of NASH17–18 and in adults with non-NASH NAFLD and NASH19–22. While 
the precise contribution(s) of increased oxidative stress and/or elevated CYP2E1 activity to 
the development of NAFLD in adults is unknown, even less is known about these factors in 
the pathogenesis of NAFLD in children. Furthermore, differences in histopathology 
observed between pediatric and adult NAFLD raise the possibility that different mechanisms 
may be responsible for development of non-NASH NAFLD and NASH in children.
In the current study, our objective was to investigate a potential role for elevated lipid 
peroxidation and/or increased CYP2E1 protein expression in the pathogenesis of pediatric 
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NAFLD. We measured levels of hepatic lipid peroxidation and CYP2E1 protein expression 
in our large cohort of children with NAFLD and in children with normal liver biopsies or 
chronic hepatitis C infection (HCV) for comparison purposes. We also considered patient 
clinical characteristics, histological findings, and serum parameters for correlative studies.
Materials and Methods
Subjects
Subjects seen at the Pediatric Liver Clinic at Riley Hospital for Children (Indianapolis, IN, 
USA) who had undergone a liver biopsy for clinical reasons were identified retrospectively 
from clinical databases. The Institutional Review Board of the Indiana University School of 
Medicine reviewed the protocol and approved the study. All together, 59 children (age ≤19 
years) with biopsy-proven NAFLD (49 with NASH), 10 children (age ≤19 years) with 
normal liver biopsies (control group), and 9 children (age ≤19 years) with chronic hepatitis 
C infection with minimal activity (HCV group) were included in this study. Children 
comprising the control group did have other medical conditions, and indications for these 
children to have undergone a liver biopsy procedure are shown in Table 1. Exclusion criteria 
for all groups included alcohol intake and diagnosis of other liver diseases [including viral 
hepatitis (with the exception of HCV in the HCV group), α1-anti-trypsin disease, 
autoimmune hepatitis, and Wilson disease].
Clinical and Laboratory Measures
Patient demographic data was obtained and body mass index (BMI) was calculated for each 
child. For the laboratory evaluations, all assays were performed at the local Clarian 
Pathology clinical laboratory (Indianapolis, IN, USA). Measures included: serum alanine 
aminotransferase (ALT), serum aspartate aminotransferase (AST), serum albumin, blood 
glucose and insulin, glycosylated hemoglobin (HbA1c), and plasma lipid panel (total 
cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) 
cholesterol, and triglycerides). The homeostasis model assessment of insulin resistance 
(HOMA-IR) was calculated from fasting blood glucose and insulin levels. Medication 
histories were examined and no control subjects or NAFLD/HCV patients were taking 
compounds known to be inducers or inhibitors of CYP2E1.
Liver histology and immunohistochemistry
Percutaneous needle liver biopsies were routinely processed in the Clarian Pathology clinical 
histology laboratory (Indianapolis, IN, USA). Formalin-fixed, paraffin-embedded 
histological sections were stained with hematoxylin and eosin (H&E) and Masson 
Trichrome stains for microscopic evaluation. Biopsies were evaluated by two pathologists 
blinded to patient characteristics. Five features of NAFLD were graded histologically based 
on the NASH CRN histological scoring system published by Kleiner et al.8: steatosis 
(amount), inflammation (portal and lobular), hepatocyte ballooning (grade) and fibrosis 
(stage). Steatosis was graded on a scale from 0 to 3 according to the amount of fat that was 
present: grade 0 (<5% macrovesicular fat); grade 1 (15–33%); grade 2 (34–66%); and grade 
3 (>66%). Portal inflammation was graded on a scale from 0 to 2: grade 0 (none); grade 1 
(minimal inflammatory infiltrate); and grade 2 (greater than minimal inflammatory infiltrate) 
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and lobular inflammation was graded on a scale from 0 to 3: grade 0 (no foci); grade 1 (<2 
foci/200× magnification); grade 2 (2–4 foci/200× magnification); and grade 3 (>4 foci/200× 
magnification). Hepatocyte ballooning was graded on a scale from 0 to 2: grade 0 (none); 
grade 1 (few ballooning cells); and grade 2 (many ballooning cells). Fibrosis was staged on a 
scale from 0 to 5: stage 0 (none); stage 1 (perisinusoidal with Trichrome stain required); 
stage 2 (perisinusoidal easily visible on H&E stain); stage 3 (portal/periportal only); stage 4 
(combination of periportal and zone 3); and stage 5 (bridging).
In addition, patients were assigned a diagnosis of non-NASH NAFLD, type 1 NASH, type 2 
NASH, or mixed (type 1 and type 2) NASH based on histological evaluations and the 
classification system put forth by Schwimmer et al.7. Non-NASH NAFLD was defined by 
steatosis in the absence of both fibrosis and hepatocyte ballooning. Type 1 (or “adult”) 
NASH was defined by a pattern similar to adult NASH, with steatosis, hepatocyte 
ballooning, and perisinusoidal fibrosis with zone 3 predominance. Type 2 (or “pediatric”) 
NASH was defined by steatosis and predominance of portal injury (including inflammation 
and/or fibrosis). Mixed (type 1 and type 2) NASH was defined by an overlap of features 
from both type 1 and type 2 NASH (often, this was type 2 NASH with hepatocyte 
ballooning and/or perisinusoidal fibrosis).
Immunohistochemistry was performed on 4 micron thick sections cut from formalin-fixed 
paraffin-embedded tissue. Briefly, the sections were deparaffinized and heat-induced antigen 
retrieval was carried out with EDTA in a pressure cooker. Endogenous peroxidase was 
quenched by incubating with hydrogen peroxidase. Sections were incubated with anti-MDA 
antibody (Abcam, Inc., Cambridge, MA, USA) or anti-CYP2E1 antibody (LifeSpan 
Biosciences, Seattle, WA, USA) and subsequently with a secondary antibody (EnVision+ 
from DAKO, Carpintenia, CA, USA). The reaction was developed using strepavidin labeled 
with horse radish peroxidase and 3,3′ diaminobenzidine (DAB) as the chromogen. 
Appropriate positive and negative control staining was performed. Immunohistochemical 
staining and steatosis was digitally quantitated and expressed as a percent of total liver 
biopsy area using SPSS Sigma Scan Pro 5.0 software (SPSS Inc., Chicago, IL, USA).
Statistical analysis
Basic descriptive statistics, including means, standard deviations (SD), and percentages were 
used to characterize the study patients. Because the data lacked a normal distribution, the 
Kruskal-Wallis test was used to make comparisons among patient groups and controls. 
Spearman rank correlations were used to detect the associations between lipid peroxidation 
levels and CYP2E1 protein content and patient clinical characteristics, histological findings, 
and serum parameters. When appropriate, stepwise regression analysis was performed to 
take into account the linear effect of several independent variables predicting the dependent 
variables (lipid peroxidation levels and CYP2E1 protein content). Statistical analyses were 
performed using SPSS 16.0 for Windows (SPSS Inc., Chicago, IL, USA). A p-value <0.05 
was considered statistically significant.
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Results
Immunohistochemical analyses
Immunohistochemistry and digital image quantification was used to measure hepatic lipid 
peroxidation and CYP2E1 protein content, and a set of representative images for all patient 
groups and controls is shown in Figure 1. Lipid peroxidation, as measured by MDA staining, 
was lowest in normal and chronic HCV liver biopsies (panels A and B), and significantly 
greater in patients with non-NASH NAFLD (panel C), type 1 NASH (panel D), type 2 
NASH (panel E), and mixed NASH (panel F). Hepatic CYP2E1 protein expression was not 
different between the control, HCV, and all NAFLD patient groups (panels G–L). As 
described below, there were no significant differences in lipid peroxidation or CYP2E1 
protein expression levels when comparisons were made across the NAFLD patient cohort.
Comparison of control, HCV, and NAFLD groups
Demographic and histological data from all subjects (control, HCV, and all NAFLD 
patients) are shown in Table 2. Compared to children with normal liver histology or HCV 
infection, pediatric NAFLD patients had significantly greater hepatic lipid peroxidation 
(p<0.001) and steatosis measured by digital quantification (p<0.001). CYP2E1 protein 
content did not differ among the three groups (p=0.116). It is important to note that children 
with normal liver biopsies or chronic HCV infection and NAFLD patients did not differ 
significantly with respect to serum ALT or AST concentrations, and a number of children in 
the control and HCV groups did display lobular and/or portal inflammation, along with 
hepatocyte ballooning, upon liver biopsy evaluation.
Comparison of non-NASH NAFLD and NASH groups
Demographic and histological data from all NAFLD patients, separated into non-NASH 
NAFLD and NASH groups, is depicted in Table 3. All liver biochemistries measured (ALT, 
AST, and albumin) were significantly greater (p<0.05) in the pediatric NASH patients 
compared to children with non-NASH NAFLD. However, the amount of hepatic lipid 
peroxidation, CYP2E1 protein content, and steatosis measured by digital quantification did 
not differ between non-NASH NAFLD and NASH groups.
Comparison within NASH groups
Demographic and histological data from the NASH patient group, divided into subtypes 
(type 1, type 2, and mixed), is presented in Table 4. Four children were not characterized by 
NASH subtype due to the small size of their liver biopsy material and therefore were not 
included in this table. Of the remaining 45 pediatric patients, 21 had type 1 NASH (47%), 19 
had type 2 NASH (42%), and 5 had mixed NASH (11%). Children with type 1 NASH were 
significantly older (p<0.001), but no other demographic or clinical laboratory measures 
differed significantly among the NASH group subtypes. Although there were no significant 
differences in CYP2E1 protein content or steatosis, there was a trend (p=0.066) for MDA 
staining to be greatest in type 1 NASH, lower in type 2 NASH, and lowest in mixed NASH.
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Variables associated with hepatic MDA content in the entire patient cohort
Univariate analysis revealed a significant correlation between hepatic MDA and age 
(r=0.433; p<0.001), BMI (r=0.602; p<0.001), and steatosis measured by digital image 
analysis (r=0.526; p<0.001). Upon stepwise regression, both BMI (r=0.549; p<0.001; Figure 
2) and amount of steatosis (r=0.255; p=0.013) were independently associated with hepatic 
lipid peroxidation levels.
Variables associated with hepatic CYP2E1 protein content in the entire patient cohort
Univariate analysis showed a significant correlation between hepatic CYP2E1 protein 
expression and BMI (r=0.283; p=0.021) and HDL cholesterol levels (r=−0.309; p=0.041). 
Upon stepwise regression analysis, only BMI (r=0.458; p=0.002; Figure 2) was identified as 
a significant independent predictor of hepatic CYP2E1 protein content.
Discussion
As the incidence of NAFLD in both the general and pediatric populations continues to 
increase, additional studies are clearly needed to define the pathogenesis and progression of 
these common liver diseases. Importantly, limited evidence suggests that histological lesions 
and clinical predictors of NASH differ between adults and children. Therefore, factors that 
play a role in the pathogenesis of adult NAFLD cannot be assumed to be involved in 
pediatric disease and must be directly examined in this patient subgroup. In the current 
study, we investigated whether elevated hepatic lipid peroxidation and CYP2E1 protein 
expression are present in pediatric NAFLD, as is observed in adult disease. We found that, 
compared to children with normal liver histology or chronic HCV infection, pediatric non-
NASH NAFLD and NASH patients had significantly elevated hepatic levels of lipid 
peroxidation. However, these parameters did not differ across the subtypes of pediatric fatty 
liver disease (non-NASH NAFLD, type 1 NASH, type 2 NASH, and mixed NASH). We also 
noted that, similar to adults, there was a significant positive relationship between BMI and 
hepatic CYP2E1 protein content in our pediatric patient cohort.
Elevations in both hepatic and systemic lipid peroxidation levels in adult NAFLD have been 
previously reported14–16. In addition, animal models have revealed that CYP2E1 plays a key 
role in the generation of oxidative stress and lipid peroxidation in the liver18 and several 
studies have demonstrated that adult NAFLD is associated with increased hepatic CYP2E1 
protein expression and activity19–22. In our pediatric cohort, children with NAFLD displayed 
a significant increase in hepatic MDA content compared to children with normal liver 
biopsies or chronic HCV infection, but CYP2E1 protein content was not elevated. We also 
did not observe any significant differences in lipid peroxidation levels or CYP2E1 
expression among the different subtypes of pediatric NASH or in children with non-NASH 
NAFLD. This is consistent with a previous study by Chtioui et al. in which in vivo hepatic 
CYP2E1 activity (measured by oral chlorzoxazone clearance) and hepatic CYP2E1 protein 
expression (assessed by immunohistochemical staining) did not differ between 10 adults 
with non-NASH NAFLD and 30 adults with NASH21. However, within the pediatric NASH 
subtypes we did detect a non-significant trend (p=0.066) for MDA staining to be greatest in 
type 1 NASH, lower in type 2 NASH, and lowest in mixed NASH. This is in agreement with 
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the findings of MacDonald et al., in which they reported a predominance of lipid 
peroxidation (measured by MDA staining) in liver biopsies from adults with varying degrees 
of steatosis in acinar zone 316, which closely resembles the type 1 NASH pattern of pediatric 
fatty liver disease. In contrast, Sanyal et al. observed greater 3-nitrotyrosine (a marker 
similar to MDA) staining in adults with NASH compared to those with simple fatty liver14, 
and we were not able to recapitulate these findings when comparing pediatric patients with 
non-NASH NAFLD to those with NASH. Upon multivariate analysis, we found that BMI 
was independently associated with both hepatic lipid peroxidation levels and hepatic 
CYP2E1 expression in our pediatric cohort. This is consistent with previous studies 
demonstrating that obesity, which is often observed in patients with NAFLD, is 
independently associated with elevations in hepatic CYP2E1 expression and activity22–24. 
There was also a significant positive relationship between the amount of steatosis and 
hepatic MDA content. This observation in our pediatric NAFLD cohort is similar to a 
significant association between steatosis and lipid peroxidation levels previously reported in 
adults with NAFLD16.
It is important to note that a large difference in lipid peroxidation levels was seen between 
the control/HCV and NAFLD groups; however, no difference in CYP2E1 protein expression 
was observed. This indicates that non-CYP-related factors contribute to the elevated 
oxidative stress that results in increased lipid peroxidation in pediatric NAFLD. One 
possibility is hepatic steatosis itself, when fatty acids that have accumulated in the liver are 
oxidized and reactive oxygen species are produced in the process. In addition, iron overload 
is thought to play an important role in generation of highly reactive hydroxyl radicals from 
the hydrogen peroxide produced when free fatty acids undergo peroxisomal β-oxidation25. 
Another possibility is an inadequate defense against oxidative stress via depletion of 
antioxidant stores26–27. These multiple sources of oxidative stress, all with the potential to 
induce lipid peroxidation, remain largely uninvestigated in the context of pediatric NAFLD.
We also considered distribution patterns of hepatic MDA and CYP2E1 staining in our 
pediatric cohort. In adults with NAFLD, a zone 3 predominance for hepatic lipid 
peroxidation has been reported16, but we did not observe any obvious patterns in MDA 
distribution across our pediatric NAFLD patient cohort (i.e. confining of MDA staining to a 
specific acinar zone and/or to lipid droplets). Distribution of CYP2E1 protein expression in 
our pediatric NAFLD cohort was similar to that observed under conditions of elevated 
hepatic CYP2E1 content due to induction by alcohol intake, with staining throughout acinar 
zones 1, 2, and 328–29. Furthermore, hepatic CYP2E1 staining also demonstrated a slight 
association with lipid droplets in our pediatric patient group, but this relationship did not 
appear to be as strong as that originally noted by Weltman et al. in adult NASH20 or as that 
observed in our recent study of CYP2E1 protein expression in a cohort of bariatric patients 
with NASH30.
There have been several studies aimed at clarifying the histopathology, clinical and 
laboratory predictors, and progression of pediatric NAFLD7, 9, 12, 31. Although this was not 
the primary focus of our study, we did compare our patient population with those described 
in previous reports and found that histopathology features of our pediatric population 
differed slightly. Specifically, we observed almost equal numbers of children with type 1 and 
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type 2 NASH (n=21 and n=19, respectively), and only 5 children were diagnosed as having a 
mixed pattern of NASH. In comparison, Schwimmer et al. originally reported a 
predominance (51%) of type 2 NASH in a group of 100 children across the spectrum of 
NAFLD7, and Carter-Kent et al. recently found that in a cohort of 108 pediatric patients, 
82% displayed overlapping features of both type 1 and type 2 NASH12. However, similar to 
these other pediatric patient groups, children in our cohort with type 1 NASH were 
significantly older (p<0.001) than the type 2 NASH or mixed NASH. The differences in 
histopathology and the subsequent classification observed between our pediatric patient 
cohort and others reiterates the need for an improved standardized scoring system designed 
specifically with the patterns of pediatric NASH, including portal inflammation, in mind12.
This study was the first to investigate a role for elevated hepatic lipid peroxidation and/or 
increased CYP2E1 protein expression in pediatric NAFLD; however, there are several 
limitations that require mention. First, we included a control group of children with normal 
liver histology upon biopsy (but with medical conditions listed in Table 1) and children with 
chronic HCV infection for comparison purposes. Importantly, these children did have 
elevated transaminase levels and did exhibit inflammation and hepatocyte ballooning upon 
liver biopsy. In addition, the control and HCV groups were significantly younger than the 
NAFLD group (p<0.05). It is not likely that this age disparity would affect hepatic CYP2E1 
content, as several previous reports have shown no affect of age (≥1 year) on CYP2E1 
expression and/or activity32–34. Likewise, although increasing age is likely associated with 
elevated oxidative stress/lipid peroxidation levels35, the minor age differences between 
groups does not explain the large increase in MDA content in the NAFLD patient group that 
was observed. Nonetheless, comparisons with the control and HCV groups should be 
interpreted with these limitations in mind. Second, a greater number of boys (n=55) were 
included in our study as compared to girls (n=23), making it difficult to draw conclusions 
based on gender. Third, due to the retrospective nature of our study, we were unable to 
obtain enough liver tissue to perform other measures of CYP2E1 content, including mRNA 
expression, Western blotting for CYP2E1 protein expression, and in vitro CYP2E1 activity 
assays. Finally, we have tried to prevent any confounding of our study results by 
standardizing the immunohistochemical staining thresholds when measuring MDA and 
CYP2E1 staining using our digital quantification technique.
In conclusion, findings from this study demonstrate that hepatic lipid peroxidation, but not 
CYP2E1 protein content, are increased in children with NAFLD compared to those with 
normal liver histology or chronic HCV infection. We also identified BMI as a significant 
independent predictor of both hepatic lipid peroxidation levels and CYP2E1 protein 
expression. Despite these novel observations, lipid peroxidation levels and CYP2E1 protein 
content did not differ across the non-NASH NAFLD group and pediatric NASH subtypes; 
therefore, further study is required to identify additional factors that may play a role in the 
pathogenesis and progression of these potentially very different patterns of disease.
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Figure 1. Immunohistochemical assessment of liver biopsies
Representative images of lipid peroxidation levels [measured by malondialdehyde (MDA) 
staining] are shown in the left panels (A–F) and CYP2E1 staining is shown in the right 
panels (G–L) as follows: (A,G) Control; (B,H) Chronic HCV Infection; (C,I) non-NASH 
NAFLD; (D,J) Type 1 NASH; (E,K) Type 2 NASH; (F,L) Mixed NASH. Hepatic lipid 
peroxidation was significantly greater in pediatric NAFLD compared to controls and chronic 
HCV patients (compare panels A,B with panels C–F). Hepatic CYP2E1 protein content was 
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not different in children with normal biopsies or chronic HCV infection versus those across 
the spectrum of NAFLD (compare panels G,H with panels I–L).
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Figure 2. BMI is a significant independent predictor of both hepatic MDA content (r=0.549; 
p<0.001) and hepatic CYP2E1 protein content (r=0.458; p=0.002)
Lipid peroxidation levels [measured by malondialdehyde (MDA) staining] and CYP2E1 
protein content was measured in liver biopsies by immunohistochemistry followed by digital 
image quantification and is represented as the percent (%) of the total liver biopsy area that 
stained positive for MDA or CYP2E1.
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Table 1
Indications for liver biopsies of children comprising the control group
Patient Number Indication for Liver Biopsy
1 portal hypertension
2 urea cycle defect
3 follow-up after acute hepatitis
4 urea cycle defect
5 portal hypertension
6 urea cycle defect
7 urea cycle defect
8 portal hypertension
9 urea cycle defect
10 portal hypertension
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Table 2
Comparison of demographic, laboratory, immunohistochemical, and histological data for control subjects and 
children with chronic HCV or NAFLD
Control (n=10) Hepatitis C (n=9) NAFLD (n=59)
Male/Female 5/5 4/5 46/13
Age (yr) 6.8 ± 5.5 11.6 ± 1.7* 13.3 ± 3.1*#
BMI (kg/m2) 19.8 ± 5.4 19.4 ± 3.7 34.9 ± 6.7*#
Glycemic Measures
 Glucose (mg/dl) Not done 89.7 ± 10.9 98.3 ± 21.6
 Insulin (mcU/ml) Not done Not done 25.8 ± 16.9
 HOMA Not done Not done 6.4 ± 5.0
 HbA1c (%) Not done Not done 5.5 ± 1.2
Lipids
 Total Cholesterol (mg/dl) Not done Not done 169.8 ± 34.0
 LDL Cholesterol (mg/dl) Not done Not done 69.8 ± 45.3
 HDL Cholesterol (mg/dl) Not done Not done 70.2 ± 39.6
 Triglycerides (mg/dl) Not done Not done 156.4 ± 99.7
Liver Biochemistries
 ALT (U/L) 64.8 ± 57.7 64.1 ± 24.4 112.7 ± 83.4
 AST (U/L) 105.5 ± 105.8 49.6 ± 15.6 67.1 ± 40.2
 Albumin (GM/dl) 3.5 ± 0.6 4.2 ± 0.2* 4.1 ± 0.4*
Immunohistochemistry
 Malondialdehyde (MDA) content (%) 7.6 ± 9.4 7.7 ± 7.6 46.7 ± 20.8*#
 CYP2E1 protein content (%) 53.5 ± 10.7 60.0 ± 11.9 60.7 ± 8.7
 Steatosis (%) 0.4 ± 0.5 0.6 ± 0.5 10.7 ± 6.1*#
Histological Scoring
 Steatosis grade 0 0 1.8 ± 0.9*#
 Fibrosis stage 0 0.4 ± 1.1 2.4 ± 1.9*#
 Grade of lobular inflammation 0.5 ± 1.0 1.6 ± 0.7 1.1 ± 0.6#
 Grade of portal inflammation 0.3 ± 0.5 0.9 ± 0.4 0.8 ± 0.6
 Hepatocyte ballooning 0.5 ± 1.0 0 0.8 ± 0.8#
Values expressed are mean ± SD and immunohistochemical measures are as a percent of total liver biopsy area. Note that diagnoses were based on 
histological scoring criteria and statistical comparisons between groups should be interpreted accordingly.
Abbreviations: BMI, body mass index; HOMA, Homeostatic Model Assessment Method; HbA1c, glycosylated hemoglobin; LDL, low-density 
lipoprotein; HDL, high-density lipoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase.
*p<0.05 vs Control;
#p<0.05 vs Hepatitis C.
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Table 3
Comparison of demographic, laboratory, immunohistochemical, and histological data for non-NASH NAFLD 
patients and children with NASH
Non-NASH NAFLD (n=10) NASH (n=49) p-value
Male/Female 7/3 39/10
Age (yr) 12.7 ± 4.5 13.4 ± 2.7 0.684
BMI (kg/m2) 33.6 ± 8.9 35.2 ± 6.1 0.844
Glycemic Measures
 Glucose (mg/dl) 105.0 ± 32.6 96.8 ± 18.6 0.339
 Insulin (mcU/ml) 18.8 ± 9.0 27.2 ± 17.8 0.719
 HOMA 4.3 ± 2.4 6.9 ± 5.3 0.582
 HbA1c (%) 6.2 ± 2.2 5.3 ± 0.4 0.180
Lipids
 Total Cholesterol (mg/dl) 160.1 ± 19.6 171.5 ± 35.8 0.321
 LDL Cholesterol (mg/dl) 71.8 ± 34.3 69.4 ± 47.7 0.618
 HDL Cholesterol (mg/dl) 69.3 ± 38.9 70.5 ± 40.3 0.896
 Triglycerides (mg/dl) 99.9 ± 21.7 167.7 ± 105.4 0.053
Liver Biochemistries
 ALT (U/L) 77.4 ± 41.8 119.9 ± 88.1 0.045
 AST (U/L) 47.7 ± 28.1 71.0 ± 41.3 0.035
 Albumin (GM/dl) 3.9 ± 0.2 4.1 ± 0.4 0.031
Immunohistochemistry
 Malondialdehyde (MDA) content (%) 38.7 ± 19.7 48.3 ± 20.8 0.233
 CYP2E1 protein content (%) 58.5 ± 11.4 61.1 ± 8.1 0.746
 Steatosis (%) 9.5 ± 6.3 11.0 ± 6.1 0.780
Histological Scoring
 Steatosis grade 1.6 ± 1.0 1.9 ± 0.8 0.437
 Fibrosis stage 0 2.8 ± 1.8 <0.001
 Grade of lobular inflammation 0.8 ± 0.6 1.1 ± 0.6 0.169
 Grade of portal inflammation 0.4 ± 0.5 0.8 ± 0.6 0.056
 Hepatocyte ballooning 0 1.0 ± 0.8 <0.001
Values expressed are mean ± SD and immunohistochemical measures are as a percent of total liver biopsy area. Note that diagnoses were based on 
histological scoring criteria and statistical comparisons between groups should be interpreted accordingly.
Abbreviations: BMI, body mass index; HOMA, Homeostatic Model Assessment Method; HbA1c, glycosylated hemoglobin; LDL, low-density 
lipoprotein; HDL, high-density lipoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase.
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Table 4
Comparison of demographic, laboratory, immunohistochemical, and histological data across NASH subtypes
Type 1 NASH (n=21) Type 2 NASH (n=19) Mixed NASH (n=5) p-value
Male/Female 16/5 16/3 4/1
Age (yr) 15.0 ± 1.8* 11.5 ± 2.7 13.8 ± 2.4 <0.001
BMI (kg/m2) 35.3 ± 6.1 32.7 ± 4.8 38.4 ± 4.6 0.156
Glycemic Measures
 Glucose (mg/dl) 98.5 ± 20.4 92.8 ± 17.0 104.8 ± 23.6 0.442
 Insulin (mcU/ml) 24.7 ± 16.8 26.4 ± 17.9 41.4 ± 19.0 0.204
 HOMA 6.3 ± 5.8 6.4 ± 4.3 10.8 ± 5.4 0.147
 HbA1c (%) 5.5 ± 0.4 5.2 ± 0.3 5.1 ± 0.3 0.126
Lipids
 Total Cholesterol (mg/dl) 165.6 ± 37.7 178.4 ± 36.5 185.4 ± 35.9 0.502
 LDL Cholesterol (mg/dl) 65.0 ± 52.0 78.9 ± 51.1 79.0 ± 35.7 0.560
 HDL Cholesterol (mg/dl) 72.6 ± 38.6 58.8 ± 39.1 76.0 ± 57.9 0.587
 Triglycerides (mg/dl) 161.7 ± 88.9 207.4 ± 142.4 151.6 ± 57.1 0.587
Liver Biochemistries
 ALT (U/L) 106.4 ± 55.1 128.2 ± 118.6 182.6 ± 75.6 0.109
 AST (U/L) 70.9 ± 36.6 70.2 ± 49.7 90.4 ± 38.5 0.427
 Albumin (GM/dl) 4.1 ± 0.4 4.3 ± 0.4 4.0 ± 0.2 0.286
Immunohistochemistry
 Malondialdehyde (MDA) content (%) 53.3 ± 19.5 44.3 ± 20.0 37.2 ± 8.2 0.066
 CYP2E1 protein content (%) 59.4 ± 8.2 61.7 ± 8.9 60.4 ± 4.8 0.764
 Steatosis (%) 10.1 ± 6.1 12.7 ± 6.6 7.9 ± 5.6 0.299
Histological Scoring
 Steatosis grade 1.7 ± 0.8 2.2 ± 0.9 1.4 ± 0.5 0.080
 Fibrosis stage 1.9 ± 1.8# 3.7 ± 0.9 2.8 ± 0.8 0.001
 Grade of lobular inflammation 1.3 ± 0.6 1.0 ± 0.5 1.2 ± 0.8 0.274
 Grade of portal inflammation 0.5 ± 0.5# 1.1 ± 0.6 1.4 ± 0.5 0.004
 Hepatocyte ballooning 1.4 ± 0.7* 0.5 ± 0.7 0.8 ± 0.5 0.001
Values expressed are mean ± SD and immunohistochemical measures are as a percent of total liver biopsy area. Note that diagnoses were based on 
histological scoring criteria and statistical comparisons between groups should be interpreted accordingly.
NOTE: 4 NASH patients were not characterized by NASH type and were therefore not included in this analysis.
Abbreviations: BMI, body mass index; HOMA, Homeostatic Model Assessment Method; HbA1c, glycosylated hemoglobin; LDL, low-density 
lipoprotein; HDL, high-density lipoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase.
*p<0.05 vs type 2 NASH;
#p<0.05 vs all other groups.
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